The IMMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IMMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The IMMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View IMMY Detailed Price Forecast - CNN Money||View IMMY Detailed Summary - Google Finance|
|View IMMY Detailed Summary - Yahoo! Finance||View IMMY Stock Research & Analysis - Zacks.com|
|View IMMY Trends & Analysis - Trade-Ideas||View IMMY Major Holders - Barrons|
|View IMMY Call Transcripts - NASDAQ||View IMMY Breaking News & Analysis - Seeking Alpha|
|View IMMY Annual Report - CompanySpotlight.com||View IMMY OTC Short Report - OTCShortReport.com|
|View IMMY Fundamentals - TradeKing||View IMMY SEC Filings - Bar Chart|
|View Historical Prices for IMMY - The WSJ||View Performance/Total Return for IMMY - Morningstar|
|View the Analyst Estimates for IMMY - MarketWatch||View the Earnings History for IMMY - CNBC|
|View the IMMY Earnings - StockMarketWatch||View IMMY Buy or Sell Recommendations - MacroAxis|
|View the IMMY Bullish Patterns - American Bulls||View IMMY Short Pain Metrics - ShortPainBot.com|
|View IMMY Stock Mentions - StockTwits||View IMMY Stock Mentions - PennyStockTweets|
|View IMMY Stock Mentions - Twitter||View IMMY Investment Forum News - Investor Hub|
|View IMMY Stock Mentions - Yahoo! Message Board||View IMMY Stock Mentions - Seeking Alpha|
|View Insider Transactions for IMMY - SECform4.com||View Insider Transactions for IMMY - Insider Cow|
|View IMMY Major Holdings Summary - CNBC||View Insider Disclosure for IMMY - OTC Markets|
|View Insider Transactions for IMMY - Yahoo! Finance||View Institutional Holdings for IMMY - NASDAQ|
|View IMMY Stock Insight & Charts - FinViz.com||View IMMY Investment Charts - StockCharts.com|
|View IMMY Stock Overview & Charts - BarChart||View IMMY User Generated Charts - Trading View|
Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018
Posted on Wednesday July 18, 2018
SAN DIEGO , July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...
SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion. The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery. All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure. The study group of 234 eyes received an intravitreal injection (pars plana) of 0.2 mL of Dropless®, a combination of steroid and antibiotics, at the time of surgery. The control group of 249 eyes received a standard topical regimen postoperatively.
Blog Exposure - Emergent BioSolutions and Profectus BioSciences Receive Contract from CEPI to Develop Nipah Virus Vaccine
Posted on Tuesday May 29, 2018
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company's latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. ("Profectus") to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions.
Imprimis: 1Q Earnings Snapshot
Posted on Tuesday May 15, 2018
The San Diego-based company said it had a loss of 17 cents per share. The pharmaceutical and drug compounding company posted revenue of $8.9 million in the period. In the final minutes of trading on Tuesday, ...